Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

A Study to Test Whether Different Doses of BI 690517 Alone or in Combination With Empagliflozin Improve Kidney Function in People With Chronic Kidney Disease

ClinicalTrials.gov ID: NCT05182840

Public ClinicalTrials.gov record NCT05182840. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 2, 2026, 7:18 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Randomised, Double-blind, Placebo-controlled and Parallel Dose Group Trial to Investigate Efficacy and Safety of Multiple Doses of Oral BI 690517 Over 14 Weeks, Alone and in Combination With Empagliflozin, in Patients With Diabetic and Non-diabetic Chronic Kidney Disease

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study is open to adults with chronic kidney disease. People with and without type 2 diabetes can take part in this study. The purpose of this study is to find out whether a medicine called BI 690517 improves kidney function in people with chronic kidney disease when taken alone or in combination with a medicine called empagliflozin. In the first part of the study, participants take empagliflozin or placebo as tablets every day for 2 months. Placebo tablets look like empagliflozin tablets but do not contain any medicine. In the second part, participants are divided into several groups. Depending on the group, the participants then additionally take different doses of BI 690517 or placebo as tablets for 3.5 months. In this case, placebo tablets look like BI 690517 tablets but do not contain any medicine. Participants are in the study for about 6 months. During this time, they visit the study site about 12 times. Where possible, about 4 of the 12 visits can be done at the participant's home instead of the study site. The trial staff may also contact the participants by phone or video call. Participants collect urine samples at home. These samples are then analysed to assess kidney function. At the end of the trial the results are compared between the different groups. The doctors also regularly check participants' health and take note of any unwanted effects.

Study identification

NCT ID
NCT05182840
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Boehringer Ingelheim
Industry
Enrollment
714 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jan 10, 2022
Primary completion
Jun 18, 2023
Completion
Jul 9, 2023
Last update posted
Oct 21, 2024

2022 – 2023

United States locations

U.S. sites
41
U.S. states
18
U.S. cities
37
Facility City State ZIP Site status
Aventiv Research Inc. Mesa Arizona 85206
AKDHC Medical Research Services, LLC Phoenix Arizona 85027
Clearview Medical Research, LLC Canyon Country California 91351
Pacific Renal Associates Long Beach California 90806
Amicis Research Center Northridge California 91324
Valley Clinical Trials, Inc. Northridge California 91325
California Kidney Specialists San Dimas California 91773
Colorado Kidney Care Denver Colorado 80230
Clinical Research of Brandon LLC Brandon Florida 33511
Horizon Research Group Coral Gables Florida 33134
Elixia Fort Lauderdale, LLC Fort Lauderdale Florida 33308
South Florida Research Institute Lauderdale Lakes Florida 33313
San Marcus Research Clinic, Inc. Miami Florida 33014
Total Research Group, LLC Miami Florida 33126
Horizon Research Group, LLC Miami Florida 33150
West Orange Endocrinology Ocoee Florida 34761
Pines Care Research Center Pembroke Pines Florida 33024
Elixia Tampa, LLC Temple Terrace Florida 33637
Boise Kidney and Hypertension PLLC Nampa Idaho 83687
Cedar Crosse Research Center Chicago Illinois 60607
Kansas Nephrology Research Institute, LLC Wichita Kansas 67214
Aa Mrc Llc Flint Michigan 48504
Elite Research Center, LLC Flint Michigan 48532
Clinical Research Consultants, LLC Kansas City Missouri 64111
Forte Family Practice Las Vegas Nevada 89103
New Mexico Clinical Research and Osteoporosis Center, Inc. Albuquerque New Mexico 87106
Triad Internal Medicine Asheboro North Carolina 27203
Lucas Research, Inc. Morehead City North Carolina 28557
Diabetes & Endocrinology Associates of Stark County Canton Ohio 44718
Cleveland Clinic Cleveland Ohio 44195
Heritage Valley Medical Group Beaver Pennsylvania 15009
Elixia Upland, LLC Upland Pennsylvania 19013
Monument Health Rapid City South Dakota 57701
Knoxville Kidney Center PLLC Knoxville Tennessee 37923
Research Institute of Dallas Dallas Texas 75231
Academy Of Diabetes, Thyroid And Endocrine, PA El Paso Texas 79935
PrimeCare Medical Group Houston Texas 77024
P&I Clinical Research, LLC Lufkin Texas 75904
Simcare Medical Research, LLC Sugar Land Texas 77478
Providence Medical Research Center Spokane Washington 99204
Universal Research Group, LLC Tacoma Washington 98405

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 162 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT05182840, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Oct 21, 2024 · Synced Sep 2, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05182840 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →